- Home
- GTEC vs MDCX Comparison
GTEC vs MDCX Comparison
Compare GTEC & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.83
Company Overview
Basic Information| Metric | GTEC | MDCX |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 15.9M |
| IPO Year | 2018 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GTEC | MDCX |
|---|---|---|
| Price | $0.83 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 238.6K | ★ 1.5M |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $90,694,007.00 | N/A |
| Revenue This Year | $1.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.09 | ★ N/A |
| Revenue Growth | ★ 8.04 | N/A |
| 52 Week Low | $0.47 | $0.25 |
| 52 Week High | $1.61 | $3.05 |
Technical Indicators
Market Signals| Indicator | GTEC | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 83.04 | 38.81 |
| Support Level | $0.64 | N/A |
| Resistance Level | $0.95 | $0.41 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 93.67 | 7.96 |
Price Performance
Historical Comparison GTEC
MDCX
About GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.